The current conceptualization of Alzheimer disease (AD) is driven by the amyloid
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …

Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of
the disease and continual increase in patient numbers, developing effective therapies to …

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive
memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its …

We describe a recently recognized disease entity, limbic-predominant age-related TDP-43
encephalopathy (LATE). LATE neuropathological change (LATE-NC) is defined by a …

Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the
Alzheimer disease (AD) process. Aβ accumulation begins 15–20 years before clinical …

Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiology. The
presence of extracellular β-amyloid deposition as neuritic plaques and intracellular …

Objective We examined whether plasma β-amyloid (Aβ) 42/Aβ40, as measured by a high-
precision assay, accurately diagnosed brain amyloidosis using amyloid PET or CSF p …

Abstract In 2011, the National Institute on Aging and Alzheimer's Association created
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …

Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established
biomarker of Alzheimer's disease (AD), reflecting abnormal tau metabolism in the brain …

Introduction We estimated the age-specific duration of the preclinical, prodromal, and
dementia stages of Alzheimer's disease (AD) and the influence of sex, setting …